EUVIMEDAtrasti EUVIMED
CrossrefInformacijos kortelė

Comparative performance of mFI‐5 and mFI‐11 thresholds in predicting outcomes after holmium laser enucleation of the prostate

Hasim Bakbak, Gurpremjit Singh, Ahmad Abdelaziz, Adam Williams, Juanita Velasquez Ospina, Jonathan E. Katz, Robert Marcovich, Alan Jerome Wein, Hemendra N. Shah

BJUI Compass · 2026-07 · 7 (7)

DOI: 10.1002/bco2.70244 ↗
SantraukaBibliografiniai duomenys

Santrauka

Abstract Objectives This work aimed to evaluate the safety and efficacy of holmium laser enucleation of the prostate across different degrees of frailty using the 11‐item and 5‐item modified frailty indices and to compare perioperative and postoperative outcomes across multiple frailty thresholds. Materials and Methods We retrospectively reviewed patients who underwent HoLEP at our institution between July 2017 and August 2025. Frailty was assessed using mFI‐11 (cutoffs ≥0.18, ≥0.27, ≥0.36) and mFI‐5 (≥0.40). Perioperative variables, functional outcomes, and postoperative complications were compared. Agreement between frailty definitions was assessed using Cohen's kappa. Logistic regression was used to evaluate complication risk. Results Among 857 patients, overall frailty burden was low ranging from 16.2% with mFI‐11 ≥0.36 to 52.6% with mFI‐11 ≥0.18, and 27.5% by mFI‐5 ≥0.40. Functional outcomes improved in all groups, though patients defined as frail by mFI‐11 ≥0.36 demonstrated less improvement in IPSS at 1 year and lower Qmax at select time points. Major complications were uncommon and did not demonstrate a consistent frailty gradient. Transfusion risk was higher only at mFI‐11 ≥0.36. Urinary tract infection showed a dose–response relationship with increasing mFI‐11, with approximately a 20% increase in odds per one‐point increase. Conclusions HoLEP is safe and effective across frailty definitions. Frailty cutoff selection meaningfully influences risk stratification, with mFI‐11 ≥0.36 providing the most clinically informative discrimination.

Jūsų darbui tinkamos žinios.

Nuo nemokamos pradžios ir asmeninės literatūros paieškos iki viso Research Suite.

Peržiūrėti tarifus →

Ar įtraukti visi leidėjų pilnieji tekstai?

Ne. Bibliografiniai įrašai, santraukos ir pilnieji tekstai yra skirtingas turinys. Ar pilnasis tekstas prieinamas, priklauso nuo šaltinio, Open Access ir jūsų turimų licencijų. EUVIMED planas nepakeičia papildomų leidėjų teisių.

Peržiūrėti tarifus →